Gennex Laboratories Ltd
BSE:531739

Watchlist Manager
Gennex Laboratories Ltd Logo
Gennex Laboratories Ltd
BSE:531739
Watchlist
Price: 13.85 INR -2.4% Market Closed
Market Cap: 3.4B INR
Section:
 

Relative Value

531739 doesn't have a meaningful market cap.

The Relative Value of one GENNEX stock under the Base Case scenario is hidden INR. Compared to the current market price of 13.85 INR, Gennex Laboratories Ltd is hidden .

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

GENNEX Relative Value
HIDDEN
Show
Worst Case
Base Case
Best Case

Valuation Multiples

2.1
P/S
P/S
Price to Sales
2.1
vs History
41
vs Industry
40
Median 3Y
2.3
Median 5Y
1.9
Industry
2.6
More Details
16.6
P/E
P/E
Price to Earnings
16.6
vs History
76
vs Industry
25
Median 3Y
20.4
Median 5Y
21
Industry
21.4
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
26
Median 3Y
-8.4
Median 5Y
-10.9
Industry
16.4
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-7.6
Median 5Y
-7.5
Industry
22.8
More Details
1.7
P/B
P/B
Price to Book Value
1.7
vs History
63
vs Industry
43
Median 3Y
1.8
Median 5Y
1.9
Industry
2.2
More Details
1.3
EV/S
EV/S
Enterprise Value to Sales
1.3
vs History
65
vs Industry
42
Median 3Y
1.9
Median 5Y
1.5
Industry
2.9
More Details
4.7
EV/GP
EV/GP
Enterprise Value to Gross Profit
4.7
vs History
36
vs Industry
28
Median 3Y
5
Median 5Y
4.3
Industry
5.5
More Details
11.5
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
11.5
vs History
76
vs Industry
21
Median 3Y
15.1
Median 5Y
14.7
Industry
13
More Details
13
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
13
vs History
74
vs Industry
22
Median 3Y
17.6
Median 5Y
16.6
Industry
16.5
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
27
Median 3Y
-6.3
Median 5Y
-9.9
Industry
15.6
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-6.8
Median 5Y
-7.1
Industry
18.7
More Details
1.7
EV/IC
EV/IC
Enterprise Value to IC
1.7
vs History
46
vs Industry
41
Median 3Y
1.7
Median 5Y
1.7
Industry
1.9
More Details

Multiples Across Competitors

GENNEX Competitors Multiples
Gennex Laboratories Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
IN
Gennex Laboratories Ltd
BSE:531739
3.2B INR 2.1 16.6 11.5 13
US
Eli Lilly and Co
NYSE:LLY
1T USD 16.9 54.7 36.7 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
492.8B USD 5.3 19.6 16.1 20.8
CH
Roche Holding AG
SIX:ROG
264.6B CHF 4.3 28 12 14
UK
AstraZeneca PLC
LSE:AZN
220.5B GBP 5.1 31.7 108.8 159.2
CH
Novartis AG
SIX:NOVN
216.5B CHF 4.9 18.9 12 15.5
US
Merck & Co Inc
NYSE:MRK
270.8B USD 4.2 14.2 10.1 12
DK
Novo Nordisk A/S
CSE:NOVO B
1.6T DKK 5.1 15.4 10.7 12.5
IE
Endo International PLC
LSE:0Y5F
213.9B USD 92.2 -73.2 338.7 849.2
US
Pfizer Inc
NYSE:PFE
144.6B USD 2.3 14.7 7.5 10.2
P/E Multiple
Earnings Growth PEG
IN
Gennex Laboratories Ltd
BSE:531739
Average P/E: 23.8
16.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
54.7
54%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.6
29%
0.7
CH
Roche Holding AG
SIX:ROG
28
29%
1
UK
AstraZeneca PLC
LSE:AZN
31.7
37%
0.9
CH
Novartis AG
SIX:NOVN
18.9
17%
1.1
US
Merck & Co Inc
NYSE:MRK
14.2
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
15.4
3%
5.1
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -73.2 N/A N/A
US
Pfizer Inc
NYSE:PFE
14.7
27%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IN
Gennex Laboratories Ltd
BSE:531739
Average EV/EBITDA: 400.9
11.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36.7
34%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
16.1
9%
1.8
CH
Roche Holding AG
SIX:ROG
12
5%
2.4
UK
AstraZeneca PLC
LSE:AZN
108.8
10%
10.9
CH
Novartis AG
SIX:NOVN
12
6%
2
US
Merck & Co Inc
NYSE:MRK
10.1
6%
1.7
DK
Novo Nordisk A/S
CSE:NOVO B
10.7
1%
10.7
IE
E
Endo International PLC
LSE:0Y5F
338.7
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
0%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IN
Gennex Laboratories Ltd
BSE:531739
Average EV/EBIT: 1 713.4
13
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
36%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.8
15%
1.4
CH
Roche Holding AG
SIX:ROG
14
6%
2.3
UK
AstraZeneca PLC
LSE:AZN
159.2
23%
6.9
CH
Novartis AG
SIX:NOVN
15.5
12%
1.3
US
Merck & Co Inc
NYSE:MRK
12
8%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
12.5
0%
N/A
IE
E
Endo International PLC
LSE:0Y5F
849.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.2
7%
1.5

See Also

Summary
GENNEX intrinsic value, competitors valuation, and company profile.
DCF Valuation
GENNEX stock valuation using Discount Cash Flow valuation method.
Relative Valuation
GENNEX stock valuation using valuation multiples.
Wall Street Estimates
GENNEX price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
GENNEX stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 307,800+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.